Linezolid versus daptomycin treatment for periprosthetic joint infections: a retrospective cohort study

Autor:	Takanori Saito, Kenichi Oe, Hirokazu Iida, Masayuki Hirata, Masahiro Sawada, Tomohisa Nakamura, Hiroshi Kawamura, Narumi Ueda
Jazyk:	angličtina
Rok vydání:	2019
Předmět:	Adult Male 0301 basic medicine medicine.medical_specialty Prosthesis-Related Infections lcsh:Diseases of the musculoskeletal system medicine.drug_class 030106 microbiology Antibiotics Periprosthetic Cohort Studies 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Daptomycin lcsh:Orthopedic surgery Internal medicine medicine Periprosthetic joint infection Humans Infection control Orthopedics and Sports Medicine 030212 general & internal medicine Adverse effect Aged Retrospective Studies Aged 80 and over business.industry Linezolid Retrospective cohort study Implant retention Middle Aged Anti-Bacterial Agents lcsh:RD701-811 chemistry Female Surgery Implant Adverse event rates lcsh:RC925-935 business Research Article Follow-Up Studies medicine.drug
Zdroj:	Journal of Orthopaedic Surgery and Research, Vol 14, Iss 1, Pp 1-8 (2019) Journal of Orthopaedic Surgery and Research
DOI:	10.1186/s13018-019-1375-7
Popis:	Background Linezolid (LZD) and daptomycin (DAP) are predominantly used to target gram-positive pathogens; however, treatment effectiveness and adverse reactions for periprosthetic joint infections (PJIs) remain unknown. The aim of this study was to compare the effectiveness and adverse reactions of LZD and DAP for PJIs. Methods This study retrospectively evaluated 82 patients between June 2009 and December 2017, to compare the effectiveness of LZD (group L, n = 39) and DAP (group D, n = 43) for treatment of PJIs harboring gram-positive microorganisms. Surgical options used with LZD or DAP therapy included implant retention, implant removal, and a shift to another appropriate antibiotic. Infection control was defined as not requiring implant removal after the final treatment. Results Gram-positive pathogens were isolated from 72% of group L and 70% of group D patients, respectively. Whole infection control rates against gram-positive pathogens in groups L and D were 79% and 77%, respectively. Furthermore, infection control rates were 94% and 58% in group L and 75% and 80% in group D, without and with implant removal, respectively. Significantly higher clinical success rates and lower adverse event rates were observed in group D, including higher red blood cell and platelet counts and lower C-reactive protein (CRP) levels. Conclusions Although the effectiveness of LZD and DAP was equivalent in terms of infection control rates for refractory PJIs with gram-positive pathogens, DAP therapy significantly decreased CRP levels and caused fewer adverse events than LZD treatment.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a010cb6311575f6d7385dbccca55eff1 http://link.springer.com/article/10.1186/s13018-019-1375-7 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.